Blockade of costimulation between T cells and antigen-presenting cells: An approach to suppress murine Graves' disease induced using thyrotropin receptor-expressing adenovirus

Thyroid

Volumn 16, Issue 5, 2006, Pages 427-434

  Chen, Chun Rong ^a   Aliesky, Holly A ^a   Guo, Jin ^a   Rapoport, Basil ^a   McLachlan, Sandra M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADENOVIRUS VECTOR; ANTIBODY; B7 ANTIGEN; BETA GALACTOSIDASE; CD28 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; THYROID PEROXIDASE; THYROID PEROXIDASE ANTIBODY; THYROTROPIN; THYROTROPIN RECEPTOR; THYROTROPIN RECEPTOR ANTIBODY; THYROXINE;

ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAVES DISEASE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOMODULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOASSAY; T LYMPHOCYTE;

ADENOVIRIDAE; ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD28; ANTIGENS, CD40; CD40 LIGAND; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAVES DISEASE; HYPERTHYROIDISM; MICE; MICE, INBRED BALB C; MODELS, BIOLOGICAL; PROTEIN BINDING; RECEPTORS, THYROTROPIN; T-LYMPHOCYTES;

EID: 33745209440     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2006.16.427     Document Type: Article

References (28)

1. Nagayama Y, Kita-Furuyama M, Ando T, Nakao K, Mizuguchi H, Hayakawa T, Eguchi K, Niwa M 2002 A novel murine model of Graves' hyperthyroidism with intramuscular injection of adenovirus expressing the thyrotropin receptor. J Immunol 168:2789-2794.
2. Ando T, Imaizumi M, Graves P, Unger P, Davies TF 2003 Induction of thyroid-stimulating hormone receptor autoimmunity in hamsters. Endocrinology 144:671-680.
3. Chen C-R, Pichurin P, Nagayama Y, Latrofa F, Rapoport B, McLachlan SM 2003 The thyrotropin receptor autoantigen in Graves' disease is the culprit as well as the victim. J Clin Invest 111:1897-1904.
4. McLachlan SM, Nagayama Y, Rapoport B 2005 Insight into Graves' hyperthyroidism from animal models. Endocr Rev 26:800-832.
5. Pichurin PN, Chen C-R, Nagayama Y, Pichurina O, Rapoport B, McLachlan SM 2004 Evidence that factors other than particular thyrotropin receptor T cell epitopes contribute to the development of hyperthyroidism in murine Graves' disease. Clin Exp Immunol 135:391-397.
6. Nagayama Y, Mizuguchi H, Hayakawa T, Niwa M, McLachlan SM, Rapoport B 2003 Prevention of autoantibody-mediated Graves'-like hyperthyroidism in mice with IL-4, a Th2 cytokine. J Immunol 170:3522-3527.
7. Nagayama Y, Watanabe K, Niwa M, McLachlan SM, Rapoport B 2004 Schistosoma mansoni and alpha-galactosylceramide: Prophylactic effect of Th1 Immune suppression in a mouse model of Graves' hyperthyroidism. J Immunol 173:2167-2173.
8. Nagayama Y, McLachlan SM, Rapoport B, Oishi K 2004. Graves' hyperthyroidism and the hygiene hypothesis in a mouse model. Endocrinology 145:5075-5079.
9. Saitoh O, Mizutori Y, Takamura N, Yamasaki H, Kita A, Kuwahara H, Nagayama Y 2005 Adenovirus-mediated gene delivery of interleukin-10, but not transforming growth factor beta, ameliorates the induction of Graves' hyperthyroidism in BALB/c mice. Clin Exp Immunol 141:405-411.
10. Nagayama Y, Saitah O, McLachlan SM, Rapoport B, Kano H, Kumazawa Y 2004. TSHR receptor-adenovirus-induced Graves' disease is attenuated in both interferon-g and interleukin-4 knockout mice: Implications for the Th1/Th2 paradigm. Clin Exp Immunol 138:417-422.
11. Land KJ, Gudapati P, Kaplan MH, Seetharamaiah GS 2006 Differential requirement of Stat4 and Stat6 in a thyrotropin receptor-289-adenovirus induced model of Graves' hyperthyroidism. Endocrinology 147:111-119.
12. Grewal IS, Flavell RA 1996 A central role of CD40 ligand in the regulation of CD4+ T-cell responses. Immunol Today 17:410-414.
13. Bluestone JA 1995 New perspectives of CD28-B7-mediated T cell costimulation. Immunity 2:555-559.
14. Carayanniotis G, Masters SR, Noelle RJ 1997 Suppression of murine thyroiditis via blockade of the CD40-CD40L interaction. Immunology 90:421-426.
15. Rao S, Vasu C, Martinez O, Kaithamana S, Prabhakar BS, Holterman MJ 2001 Targeted delivery of anti-CTLA-4 antibody downregulates T cell function in vitro and in vivo. Clin Immunol 101:136-145.
16. Takiguchi M, Murakami M, Nakagawa I, Saito T, Hashimoto A, Uede T 2000 CTLA4IgG gene delivery prevents autoantibody production and lupus nephritis in MRL/lpr mice. Life Sci 66:991-1001.
17. Mihara M, Tan I, Chuzhin Y, Reddy B, Budhai L, Holzer A, Gu Y, Davidson A 2000 CTLA4Ig inhibits T cell-dependent B-cell maturation in murine systemic lupus erythematosus. J Clin Invest 106:91-101.
18. Quattrocchi E, Dallman MJ, Feldmann M 2000 Adenovirus-mediated gene transfer of CTLA-4Ig fusion protein in the suppression of experimental autoimmune arthritis. Arthritis Rheum 43:1688-1697.
19. Guillot C, Mathieu P, Coathalem H, Le Mauff B, Castro MG, Tesson L, Usal C, Laumonier T, Brouard S, Soulillou JP, Lowenstein PR, Cuturi MC, Anegon I 2000 Tolerance to cardiac allografts via local and systemic mechanisms after adenovirus-mediated CTLA41g expression. J Immunol 164:5258-5268.
20. Jiang GP, Hu ZH, Zheng SS, Jia CK, Zhang AB, Wang WL 2005 Adenovirus mediated CTLA4Ig gene inhibits infiltration of immune cells and cell apoptosis in rats after liver transplantation. World J Gastroenterol 11:1065-1069.
21. Guillot C, Guillonneau C, Mathieu P, Gerdes CA, Menoret S, Braudeau C, Tesson L, Renaudin K, Castro MG, Lowenstein PR, Anegon I 2002 Prolonged blockade of CD40-CD40 ligand interactions by gene transfer of CD40Ig results in long-term heart allograft survival and donor-specific hyporesponsiveness, but does not prevent chronic rejection. J Immunol 168:1600-1609.
22. Potiron N, Chagneau C, Boeffard F, Soulillou JP, Anegon I, Le Mauff B 2005 Adenovirus-mediated CTLA4Ig or CD40Ig gene transfer delays pancreatic islet rejection in a rat-to-mouse xenotransplantation model after systemic but not local expression. Cell Transplant 14:263-275.
23. Guo J, Pichurin P, Nagayama Y, Rapoport B, McLachlan SM 2003 Insight into antibody responses induced by plasmid or adenoviral vectors encoding thyroid peroxidase, a major thyroid autoantigen. Clin Exp Immunol 132:408-415.
24. Mittereder N, March KL, Trapnell BC 1996 Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol 70:7498-7509.
25. Chen C-R, Pichurin P, Chazenbalk GD, Aliesky H, Nagayama Y, McLachlan SM, Rapoport B 2004 Low-dose immunization with adenovirus expressing the thyroid-stimulating hormone receptor A-subunit deviates the antibody response toward that of autoantibodies in human Graves' disease. Endocrinology 145:228-233.
26. Geutskens SB, van der Eb MM, Plomp AC, Jonges LE, Cramer SJ, Ensink NG, Kuppen PJ, Hoeben RC 2000 Recombinant adenoviral vectors have adjuvant activity and stimulate T cell responses against tumor cells. Gene Ther 7:1410-1416.
27. Nakagawa I, Murakami M, Ijima K, Chikuma S, Saito I, Kanegae Y, Ishikura H, Yoshiki T, Okamoto H, Kitabatake A, Uede T 1998 Persistent and secondary adenovirus-mediated hepatic gene expression using adenovirus vector containing CTLA4IgG. Hum Gene Ther 9:1739-1745.
28. Ali RR, Reichel MB, Byrnes AP, Stephens CJ, Thrasher AJ, Baker D, Hunt DM, Bhattacharya SS 1998 Co-injection of adenovirus expressing CTLA4-Ig prolongs adenovirally mediated lacZ reporter gene expression in the mouse retina. Gene Ther 5:1561-1565.